“Canary in the Coal Mine:” Navigating the 2026 Measles Resurgence After Eliminating the Disease

For decades, the US stood as a global leader in public health, having declared measles eliminated in 2000.^1,2 Today, that status is under the most severe threat in a generation.

As of February 26, 2026, the US has already seen 1136 reported measles cases across 28 jurisdictions this year alone. Following a 30-year high of 2281 cases in 2025, the current trajectory suggests the US may be on track to break annual records for the post-elimination era, according to the CDC.¹

For pharmacists on the front lines, this resurgence is not merely a statistical anomaly, but a clinical and communication crisis fueled by shifting government policies and a deepening well of vaccine hesitancy.

A Wakeup Call for Public Health

As Demetre Daskalakis, MD, MPH, tells Drug Topics, the current outbreaks as a “canary in the coal mine” for the American health care system. He notes that measles—the most contagious virus currently known—serves as a vital sign for the collective ability to maintain community-wide immunity.

The resurgence carries a staggering price tag. Managing a single measles case—involving intensive contact tracing, quarantining, and testing—can cost nearly $60,000.

“There are always tradeoffs in public health,” Daskalakis said, noting that these outbreaks force pediatricians and providers to pivot resources away from chronic disease management to contain a preventable spread.

Beyond the immediate fiscal and logistical strain, the clinical toll on children is profound. Measles can lead to immune amnesia, effectively wiping out the body’s memory of other diseases and leaving survivors immunologically vulnerable for years.

READ MORE: Administrative Shifts in Vaccine Guidance and What Pharmacists Need to Know

Policy Pivots From Mandates to Personal Choice

Central to the current crisis is a fundamental shift in how the federal government disseminates vaccine information. Although top officials acknowledge the measles, mumps and rubella (MMR) vaccine as the most effective protection, the current presidential administration has increasingly framed vaccination as a personal choice rather than a public health necessity.³

Criticism has intensified regarding the influence of US Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr, a longtime vaccine skeptic who has suggested remedies like vitamin A and cod liver oil as ways to prevent measles.^2,3 Although vitamin A can be used to treat deficiencies caused after an infection, experts emphasize it cannot prevent the infection itself.^2,4 Furthermore, Kennedy reportedly directed the CDC to alter website language to leave open the long-debunked question of whether vaccines cause autism.³

“Promoting vaccination, not this sense of ‘Well, you know, it’s just a matter of choice,’” is what is needed, Richard Besser, MD, former acting head of the CDC, said to Axios.

Currently, the CDC is operating without a full-time political leader following the firing of Susan Monarez over a dispute regarding changing vaccine recommendations.⁵

Protecting the Vulnerable Through Herd Immunity

For Crystal Hodge, PharmD, BCIDP, an adult inpatient pharmacist in Texas, the policy shift has direct consequences for her most at-risk patients. Because the MMR vaccine is a live attenuated vaccine, it cannot be safely administered to patients who are immunocompromised, including those undergoing cancer treatment or organ transplants.⁴

“Our immunocompromised population relies on the immunocompetent population to get vaccinated to prevent the spread,” Hodge said. She emphasizes that in a susceptible population, 1 infected individual will infect 12 to 18 additional patients on average.

The math for safety is uncompromising as a community vaccination rate of 95% is required to prevent large outbreaks.^1-3 However, US national MMR coverage among kindergartners has slipped to 92.5%, leaving approximately 286,000 children at risk. In some outbreak zones, such as Spartanburg County, South Carolina, school vaccination rates have plummeted to as low as 21%.^1,3

READ MORE: As Immunization Schedules Change, Vaccine Confidence Among Patients Falters

The Pharmacist’s Role in Mitigation and Communication

Pharmacists are uniquely positioned to bridge the information gap created by conflicting government messaging. Experts suggest several strategies to mitigate the spread and inform patients.

Measles presents with high fever, cough, runny nose, and conjunctivitis 2 to 5 days before the characteristic rash appears. Because patients are contagious 4 days before the rash, early identification is critical for isolation. For nonimmune-eligible patients exposed within the last 72 hours, the MMR vaccine is the preferred post-exposure prophylaxis. For those who cannot receive the vaccine—infants under 6 months and those pregnant or immunocompromised—immune globulin may be used within 6 days of exposure.⁴

Hodge also told us that “pure myth-busting” is often ineffective. Instead, pharmacists should utilize motivational interviewing or normalize routine vaccinations as standard care to reach hesitant parents. Pharmacists should also leverage the CDC’s “Be Ready for Measles" toolkit as well as summaries from the Infectious Diseases Society of America (IDSA) and the Society of Infectious Diseases Pharmacists (SIDP) to educate both staff and patients.¹

The Road Ahead

Despite these newfound and nationwide challenges, the international community, however, is watching. The Pan American Health Organization has scheduled a review for November 2026 to determine if the US has officially lost its measles-free elimination status. This status is revoked when the same virus lineage circulates uninterrupted for 12 months.⁶

As policy debates continue in Washington DC, the clinical reality remains. Measles is still a preventable crisis. For pharmacists, they must provide evidence-based education, advocate for the 95% herd immunity threshold and serve as the reliable source of truth in an era of growing medical misinformation and confusion, as both Hodge and Daskalakis said.

“Public health needs to navigate the new normal of vaccine hesitancy and doubt. As these sentiments become more pervasive in some populations, so will measles and other vaccine preventable diseases,” Daskalakis said. “The current policy environment in many states that facilitates avoidance of vaccination—many now with vaccine exceptions over 5%, making 95% population immunity impossible—will need to be revisited with an eye toward being responsive to misinformation in a meaningful way.”

READ MORE: Immunization Resource Center

Are you ready to elevate your pharmacy practice? Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips, straight to your inbox.

REFERENCES

1. Measles cases and outbreaks. CDC. February 27, 2026. Accessed March 5, 2026. https://www.cdc.gov/measles/data-research/index.html

2. Yang J, Young K. What’s behind the growing measles outbreak and how the Trump Administration is responding. PBS News. March 8, 2025. Accessed March 5, 2026. https://www.pbs.org/newshour/show/whats-behind-the-growing-measles-outbreak-and-how-the-trump-administration-is-responding

3. Sullivan P. New measles surge revives doubts over fed response. Axios. March 4, 2026. Accessed March 5, 2026. https://www.axios.com/2026/03/04/measles-cases-outbreak-vaccine-trump

4. Girotto J. Measles is back, what should you know? UConn School of Pharmacy and Pharmaceutical Sciences. February 12, 2026. Accessed March 5, 2026. https://pharmacy.uconn.edu/2026/02/12/measles-is-back-what-should-you-know/

5. Stone W, Simmons-Duffin S. Ousted CDC director testifies she was fired for resisting pressure from RFK Jr. NPR. September 17, 2025. Accessed March 5, 2026. https://www.npr.org/sections/shots-health-news/2025/09/17/nx-s1-5544143/cdc-director-susan-monarez-testimony-rfk

6. Update on the review of measles elimination status. Pan American Health Organization. March 2, 2026. Accessed March 5, 2026. https://www.paho.org/en/news/2-3-2026-update-review-measles-elimination-status